Organic compounds -- part of the class 532-570 series – Organic compounds – Fatty compounds having an acid moiety which contains the...
Reexamination Certificate
2008-07-08
2008-07-08
Jiang, Shaojia Anna (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Fatty compounds having an acid moiety which contains the...
C514S557000, C514S559000, C554S117000, C554S119000, C562S503000
Reexamination Certificate
active
10994364
ABSTRACT:
Disclosed is a method for treatment of external secretion disorders, which comprises administering a fatty 5 acid derivative to a subject in need of said treatment. The method of the present invention is useful for treatment of at least one condition selected from hypolacrimation including disorder of basal tear secretion, dry-eye syndrome, hyposalivation and dry-mouth syndrome.
REFERENCES:
patent: 4388324 (1983-06-01), Horribin
patent: 4535093 (1985-08-01), Horribin
patent: 5164415 (1992-11-01), Ueno
patent: 5212324 (1993-05-01), Ueno
patent: 5369127 (1994-11-01), Burk et al.
patent: 5686487 (1997-11-01), Ueno
patent: 5696166 (1997-12-01), Yanni et al.
patent: 6211197 (2001-04-01), Belley et al.
patent: 0284810 (1988-05-01), None
patent: 0 308 135 (1989-03-01), None
patent: 0453127 (1991-10-01), None
patent: 0 503 887 (1992-09-01), None
patent: 0690049 (1996-01-01), None
patent: P9502004 (1994-04-01), None
patent: 2-32055 (1990-02-01), None
patent: WO 94/24121 (1994-10-01), None
patent: WO 00/38663 (2000-07-01), None
patent: WO 00/38690 (2000-07-01), None
U.S. Appl. No. 11/399,495, filed Aug. 2006, Ueno, Ryuji.
U.S. Appl. No. 11/366,413, filed Mar. 2006, Ueno, Ryuji.
Hall et al. “Structure-Activity Relationships in a Series of 11-deoxy Prostaglandins” Prostaglandins (1976) vol. 11, No. 3, pp. 573-587.
D. F. Horrobin et al.; Sjogren's Syndrome and the Sicca Syndrome: The Role of Postaglandin E1 Deficiency. Treatment with Essential Fatty Acids and Vitamin C; Medical Hypotheses; vol. 6, pp. 225-232, 1980.
C. Pholpramool; Secretory Effect of Prostaglandins on the Rabbit Lacrimal Gland In Vivo; Prostaglandins and Medicine, vol. 3, pp. 185-192, 1979.
Norio Taira and Susumu Satoh; Differential Effects of Tetrodotoxin on the Sialogenous and Vasodilator Actions of Prostaglandin E2in the Dog Salivary Gland; Life Sciences, vol. 15, pp. 987-993, 1974.
Norio Taira and Susumu Satoh; Prostaglandin F2αas a Potent Excitant of the Parasympathetic Postganglionic Neurons of the Dog Salivary Gland, Life Sciences, vol. 13, pp. 501-506, 1973.
Russian Official Action, Application No. 2002103597/15(004431), Application filing date: Jul. 13, 2000, Application No. PCT/JP 00/04696, Appln. NoEA, Applicant(s): Sucampo AG, CH.
Follmann et al. Klinische Monatsblatter Fur Augenheilkunde, (Jan. 1980) 176(1) 147-52. (in German, English Abstract).
N. Taira et al., “Mode of actions of prostaglandin E2, Flaipha and F2 alpha in the dog salivary gland”, INT Union Pharmacol Proceedings of the International Congress of Pharmacology 1977, p. 159 XP001011501.
N. Taira et al. “Prostaglandin F2alpha as a potent excitant of the parasympathetic postganglionic neuron of the dog salivary gland” Life Sciences, vol. 13., No. 5,1973, pp. 501-506, XP001011455.
N. Taira et al. “Differential effects of tetrodotoxin on the sialogenous and vasodilator action of prostaglandin E2 in the dog salivary gland” Life Sciences, vol. 15, No. 5,1974, pp. 987-993, XP001011500.
C. Pholpramoo et aL “Secretory effect of prostaglainds on the rabbit lacrimal gland in vied” Prostaglandin and medicine, vol. 3, No. 3,1979, pp. 185-192, XP001011481.
F.M.C. De Farias “Prostaglandin analogues the synthesis of new prostanoids from natural safrole” Quimica Nova, vol. 7, No. 2,1984, pp. 111-112, XP001011499.
R.A. Hahn, et al. “Salivation induced by prostaglandin F2ac and modification of the response by atropine and physostigmine” Br. J. Pharinaco (1972), 44, 527-533.
R.A. Hahn, et aL “Further observations on the interaction of prostaglandin Fzac with cholinergic mechanisms in canine salivary glands” European Journal of Pharmacology 25 (1974) vol. 25, No. 3 279-286.
N. Taira et al. “Differential block by 1-hyoscyamine of the salivary and vascular-response of the dog msndi'bular gland to prostaglandin F2ac” Life Sciences vol. 17, No. 12: 1869-1876(1975).
J.H. Yu, et al. Prostaglandin E1 induced salivary secretion; Experientica 38(1982), 1077-1078.
B.H. Kim “Studies on the effects of prostaglandin and biadykinin on salivary flow, blood flow and cyclic Nucleotide contents in the submaxillary gland of cat” Journal of Osaka Dental University vol. 16, No. 1: 52-66 (1982).
M. Rodrigues, et al. “Prostaglandin as biochemical markers of radiation injury to the salivary glands after iodine-131 therapy” European Journal of Nuclear Medicine vol. 25, No. 3:265-269 (1998).
S.M.M. Katrim, et at “Effect of Topical prostaglandin on Nasal, Patency In Man” Prostaglandin vol. 15, No. 3:457-462, 1978.
S.M.M. Karim, et al. “Effect of 17 Phenyl PGF2a On Nasal Patency In Man”, Prostaglandin and Medicine vol. 3, No. 1: 33-37, 1979.
C. Pholpramool “Secretory Effect of Prostaglandin On the Rabbit Lacrimal Gland In Vivo” Prostaglandin and Medicine 3:185-192, 1979.
D.F. Horrobin, et al. “Sjogren's Syndrome and theSicca Syndrome: The Role of Prostaglandin E, Deficiency. Treatment with Essential Fatty Acids and Vitamin C” Medical Hypotheses, 6:225-232,1980.
Robert J. R. McKendry “Treatment of Sjogren's Syndrome with Essential Fatty Acids, Pyridoxine and Vitamin C” Prostaglandin Leukotriences and Medicine vol. 8, No. 4:403-408, 1982.
C. Pholpramool, et aL “Evidence for the Requirement of Sympathetic Activity in the POE,—Induced Iscrimal Secretion in Rabbits” Arch Int. Phamracodyn 265:128-137 (1983).
R Manthorpe, et aL “Primary Sjogren's syndrome treated with Efamol/Efavit. A double blind cross-over investigation” Rheumatol Int. (1984) 4:165-167.
P. Aragona, et al. “Effects of a Stable Analogue of POE2 (11-deoxy-13,14-didehydro-16 (s)-methylester methyl POE2: FCE 20700) on the Secretory Processes of Conjunctiva) Goblet Cells of Rabbit” Exp. Eye Res. vol. 45, No. 5: 647-654,1987.
Yasumasa Goh, et al. “Ocular Hypotensive and Adverse Effects After Topical Application of Prostaglandin Analogue, 5-1033, In Animate: A Comparative Study with OF-021 and PHXA34” Japan L Ophthslmnl 38:215-227,1994.
Hirosbi Toshida, et aL “Effects on Tear Secretion of Isopropyl Unoprostone Eye Drops in Rabbits” Folia Ophthalmol Japan 47:1323-1328 (1996.
Jiang Shaojia Anna
Olson Eric S
Sucampo AG
LandOfFree
Compound for treatment of external secretion disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compound for treatment of external secretion disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound for treatment of external secretion disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3941457